| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today announces that the Central Drugs Standard Control Organization (CDSCO) approved Dream Sock® for distribution. This marks a significant milestone for the Company as it now prepares to launch its integrated monitoring devices, including Dream Sock®, Dream Sight™, and Dream Duo™, across India in early 2026.
With approval from the CDSCO, India's national regulatory body for cosmetics, pharmaceuticals, and medical devices, Owlet becomes one of the few infant health technology companies to meet the region's stringent medical device requirements, further validating its commitment to clinical rigor and innovation. As smartphone penetration exceeds 80% in urban centers, India's connected-home environment provides a strong foundation for the adoption of Owlet's technology.
Posted In: OWLT
